Mangoceuticals, Inc. Common Stock (MGRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has a cash flow conversion efficiency ratio of -0.079x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.24 Million) by net assets ($15.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mangoceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MGRX current and long-term liabilities for a breakdown of total debt and financial obligations.
Mangoceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TAIZHOU WATER GRP. H YC 1
F:GX5
|
N/A |
|
Hays plc
LSE:HAS
|
0.122x |
|
GACM Technologies Limited
NSE:GATECH
|
N/A |
|
Avon Protection PLC
LSE:AVON
|
0.096x |
|
TESGAS S.A.
WAR:TSG
|
-0.092x |
|
Silver Wolf Exploration Ltd
V:SWLF
|
-0.069x |
|
Ecclesiastical Insurance Office plc
LSE:ELLA
|
0.006x |
|
SC Estate Builder Bhd
KLSE:0109
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Mangoceuticals, Inc. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Mangoceuticals, Inc. Common Stock (MGRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.95 Million | $-4.86 Million | -0.349x | +96.14% |
| 2023-12-31 | $774.75K | $-7.00 Million | -9.032x | -311.86% |
| 2022-12-31 | $614.03K | $-1.35 Million | -2.193x | -309.28% |
| 2021-12-31 | $-16.72K | $-17.52K | 1.048x | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more